[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Regensburg\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":104},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100627100","accelerated-treatment-of-depressive-patients-with-tdcs-100627100",false,"NCT07444242","Accelerated Treatment of Depressive Patients With tDCS","Accelerated Treatment of Depressive Patients With tDCS (Twice Per Day) - a Placebo Controlled Home-based Treatment","AcctDCS","Inclusion Criteria:\n\n* Sex: female, male, non-binary\n* Age: 18-70 years\n* Diagnosis of depression: no current or past psychiatric medication (current episode and history)\n* Provision of informed consent to participate\n* Sufficient proficiency in the German language\n\nExclusion Criteria:\n\n* Presence of contraindications for tDCS (e.g., electrical implants or metallic objects in the body such as a cardiac pacemaker or insulin pump, dermatological conditions affecting the scalp)\n* Neurological disorders (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, brain malformations, or a history of severe head injury)\n* Participation in another clinical trial on depression within the 3 months prior to treatment initiation\n* Pregnancy or breastfeeding","ALL","18 Years","70 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","A randomized, controlled three-arm study is planned to investigate the effectiveness and feasibility of an accelerated home-based tDCS application (3 weeks of transcranial direct current stimulation at home, twice daily). A total of 30 patients with depression (10 per group), who are currently not taking and have no history of taking antidepressant medication, will be randomly assigned to either an active tDCS condition, a sham (placebo) tDCS condition, or a waitlist control group. The latter two groups will receive active tDCS treatment after completion of the control phase.\n\nThis study represents a continuation of the pilot study GSUND DAHOAM (Ethics approval: 20-2091-101; Dragon et al., 2024).",[28],"Major Depressive Disorder",[30,31,32],"Depression","tDCS","Accelerated","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2026-04-01",{"date":41,"type":22},"2027-12-31",{"name":43,"class":44},"University of Regensburg","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100377950","phase-2-a-trial-to-assess-haploidentical-t-depleted-stem-cell-transplantation-in-patients-with-scd-100377950","NCT04201210","A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD","A Phase II Stratified Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With Sickle Cell Disease With no Available Sibling Donor","Inclusion Criteria:\n\n* Age 2yrs to 35yrs\n* Homozygous hemoglobin S disease or heterozygous hemoglobin SC or S 0\u002F+\n* Study specific consent given\n* Preexisting severe or moderate SCD related complications:\n\n  * Clinically significant neurological event (stroke) or deficit\n  * Silent crisis, neurocognitive deficit\n  * Pathological angio-MRI with TOF Sequence\n  * TCD velocity \\>200 cm\u002Fs at 2 occasions \\>1 month apart\n  * More than 5 vaso-occlusive crises (VOC) in the past 1 year or more than 20 VOC in a lifetime\n  * Two or more episodes of acute chest syndrome (ACS) in a lifetime or one episode of ACS in the past 24 months\n  * Chronic transfusion requirement or more than 8 transfusions or one exchange transfusion in a lifetime\n  * Transfusion-refractory allo-immunization\n  * More than five SCD-related hospitalizations in a lifetime\n  * Beginning pulmonary hypertension\n  * Osteonecrosis at more than 2 sites\n  * Beginning SCD Nephropathy\n  * Recurrent priapism (\\>2)\n\nExclusion Criteria:\n\n* Karnofsky or Lansky Performance Score \\\u003C 70%\n* Patients with donor-specific antibodies (DSA) against the potential stem cell donor by either\n\n  * Cell-based crossmatched assays (Complement-dependent cytotoxicity; CDC) or\n  * Flow cytometry crossmatch test or\n  * Solid-phase immunoassays (SPI) or\n  * Modified SPI such as C4d and C1q assays Whichever method the participating center is experienced in.\n* Patients with major AB0 incompatibility defined according to EBMT Handbook, Edition 2019 Tab 23.1.:\n\nABO incompatibility Recipient Donor Major O A O B O AB A AB B AB\n\n* Cardiac function:\n\n  * Ejection fraction at rest \\\u003C45.0% on echocardiography or\n  * Shortening fraction of \\\u003C27.0% by echocardiogram or radionuclide scan (MUGA)\n  * Patients with \\> grade II hypertension by Common Toxicity Criteria (CTC)\n* Renal function:\n\n  * Estimated creatinine clearance (for patients \\> 12 years) greater than 50.0 mL\u002Fminute\n  * for pediatric patients (\\> 1 year to 12 years), GFR estimated by the updated Schwartz formula ≥ 90.0 mL\u002Fmin\u002F1.73 m2. If \\\u003C 90 mL\u002Fmin\u002F1.73 m2, renal function must be measured by 24-hour creatinine clearance or nuclear GFR and must be \\> 70.0 mL\u002Fmin\u002F1.73 m2 or\n  * Creatinine clearance below threshold defined for stem cell transplantation according to local clinical standard\n* Pulmonary function:\n\n  * DLCO \\>50% (adjusted for hemoglobin), and FVC and FEV1≥50%; children unable to perform for PFTs, O2 saturation \\\u003C92% on room air.\n* Liver function:\n\n  * Total bilirubin \\> 2x the upper limit of normal (unless elevated bilirubin is attributed to Gilbert's Syndrome) and ALT\u002FAST \\> 2.5x the upper limit of normal.\n  * Chronic active viral hepatitis\n* Women who are pregnant (positive serum or urine βHCG) or breastfeeding. Note: Women of childbearing potential must have a negative serum pregnancy test at study entry.\n* Adults of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter,\n* History of uncontrolled autoimmune disease or on active treatment\n* Patient unable to comply with the treatment protocol\n* Prior autologous or allogeneic hematopoietic stem cell transplant\n* Vaccination with a live virus vaccine during the trial\n* HIV infection\n* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study (this includes alcoholism\u002Fdrug addiction)\n* Patients unwilling or unable to comply with the protocol or unable to give informed consent.\n* Concurrent severe or uncontrolled medical disease (e.g. uncontrolled diabetes, congestive heart failure, myocardial infarction within 6 months prior to the study, unstable and uncontrolled hypertension, chronic renal disease, or active uncontrolled infection) which by assessment of the treating physician could compromise participation in the study","2 Years","35 Years",{"count":56,"type":22},212,[58],"PHASE2","HSCT is currently the only curative option for SCD but less than 20% of SCD patients have a MD donor available. So far, all curative approaches beyond a MSD HSCT at young age are non-satisfactory. With the lack of a suitable donor for the vast majority of patients, the major question of this trial is, if a haploidentical αß\u002FCD19+ T-cell depleted HSCT can be a valid alternative to a MSD HSCT. The main challenge in non-malignant diseases is to offer a safe and GvHD-free HSCT without rejection.",[61,62,63,64,65,66],"HbS Disease","Hemoglobin S Disease","Sickle Cell Anemia","Sickle Cell Disorders","Sickling Disorder Due to Hemoglobin S","Sickle Cell Disease","2024-05-10",{"date":69,"type":37},"2024-05-13",{"date":71,"type":37},"2021-06-30",{"date":73,"type":22},"2030-03-31",{"name":43,"class":44},9,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":81,"conditions":88,"keywords":90,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100370867","longitudinal-study-of-crshipec-for-peritoneal-carcinomatoses-100370867","NCT04108936","Longitudinal Study of CRS\u002FHIPEC for Peritoneal Carcinomatoses","Longitudinal Study of the Effect of Cytoreductive Surgery and HIPEC in Patients With Peritoneal Carcinomatoses","CRS\u002FHIPEC","Inclusion Criteria:\n\n* suspicious peritoneal carcinomatosis\n\nExclusion Criteria:\n\n* \\\u003C18 years","80 Years",{"count":86,"type":22},250,"OBSERVATIONAL",[89],"Peritoneal Carcinomatosis",[91,92,93,94],"CRS","HIPEC","cellular immune response","microbiomes","2022-08-19",{"date":97,"type":37},"2022-08-23",{"date":99,"type":4},"2016-10",{"date":101,"type":22},"2028-07",{"name":43,"class":44},2,""]